Gary P Wang, MD, PhD, FIDSA
Professor Of Medicine And Division Chief
Department:
MD-INFECTIOUS DISEASES
Business Phone:
(352) 294-5481
Business Email:
gary.wang@medicine.ufl.edu
About Gary P Wang
Gary P. Wang, MD, PhD, FIDSA, is Professor of Medicine and Chief of the Division of Infectious Diseases and Global Medicine in the Department of Medicine at the University of Florida. Dr. Wang graduated from Temple University School of Medicine in 2001 with MD and PhD degrees in biochemistry and mechanistic enzymology. He completed Internal Medicine Residency at Yale-New Haven Hospital, followed by Infectious Diseases Fellowship at Hospital of the University of Pennsylvania. Upon the completion of his clinical training, Dr. Wang pursued a postdoctoral research fellowship in Microbiology, Virology and Genomics with Dr. Rick Bushman at the University of Pennsylvania. He joined University of Florida in 2009 as an Assistant Professor, became Section Chief of Infectious Diseases at North Florida/South Georgia VA in 2014, and was appointed Division Chief of Infectious Diseases and Global Medicine in 2018. Dr. Wang was promoted to Associate Professor with tenure in 2016, and Professor of Medicine in 2022.
Related Links:
Teaching Profile
Courses Taught
2019
GMS5905 Special Topics in Biomedical Sciences
2017-2018
MDT7200 Elect Top/Medicine
2017
VME6934 Topics in Veterinary Medical Sciences
2016
MDC7200 Medicine Clerkship
Board Certifications
-
Infectious DiseasesAmerican Board of Internal Medicine
Clinical Profile
Specialties
- Infectious Disease
Areas of Interest
- Fecal microbiota transplant
- HIV/AIDS
- Hepatitis C
Research Profile
Areas of Interest
- Clostridium difficile infection
- Fecal Microbiota Transplant
- Gut Microbiome
- HIV
- HIV/HCV Co-infection
- HIV/HCV Drug Resistance
- Metagenomics Sequencing
Open Researcher and Contributor ID (ORCID)
0000-0002-3457-442X
Publications
2024
Condyloma lata in an HIV patient with secondary syphilis masquerading as anal condyloma-a case report.
International journal of colorectal disease.
39(1)
[DOI] 10.1007/s00384-024-04678-9.
[PMID] 39039332.
2024
Retraction: Dealcoholized muscadine wine was partially effective in preventing and treating dextran sulfate sodium-induced colitis and restoring gut dysbiosis in mice.
Food & function.
15(6)
[DOI] 10.1039/d4fo90024c.
[PMID] 38421214.
2023
Dealcoholized muscadine wine was partially effective in preventing and treating dextran sulfate sodium-induced colitis and restoring gut dysbiosis in mice.
Food & function.
14(13):5994-6011
[DOI] 10.1039/d3fo00047h.
[PMID] 37310366.
2023
Effects of Carboxymethylcellulose Artificial Tears on Ocular Surface Microbiome Diversity and Composition, A Randomized Controlled Trial.
Translational vision science & technology.
12(8)
[DOI] 10.1167/tvst.12.8.5.
[PMID] 37555738.
2023
Muscadine grape (vitis rotundifolia) and wine polyphenols alleviated arthritis and restored the gut microbial composition in mice
The Journal of Nutritional Biochemistry.
116
[DOI] 10.1016/j.jnutbio.2023.109311.
2023
Pneumocystis jiroveciipneumonia presenting as a large pulmonary mass in a patient with AIDS
BMJ Case Reports.
16(7)
[DOI] 10.1136/bcr-2022-253563.
[PMID] 37524509.
2023
Smoking-induced subgingival dysbiosis precedes clinical signs of periodontal disease.
Scientific reports.
13(1)
[DOI] 10.1038/s41598-023-30203-z.
[PMID] 36882425.
2022
A randomized controlled trial to evaluate the effectiveness of a novel mouth rinse in patients with gingivitis.
BMC oral health.
22(1)
[DOI] 10.1186/s12903-022-02518-2.
[PMID] 36324127.
2022
Correction to: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Drugs.
82(15)
[DOI] 10.1007/s40265-022-01805-0.
[PMID] 36342618.
2022
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Drugs.
82(15):1527-1538
[DOI] 10.1007/s40265-022-01797-x.
[PMID] 36287379.
2022
Emulsification by vitamin E TPGS or Quillaja extract enhanced absorption of berberine without affecting its metabolism in humans.
Food & function.
13(23):12135-12143
[DOI] 10.1039/d2fo02288e.
[PMID] 36321951.
2022
Microbiome Resilience despite a Profound Loss of Minority Microbiota following Clindamycin Challenge in Humanized Gnotobiotic Mice
Microbiology Spectrum.
10(1)
[DOI] 10.1128/spectrum.01960-21.
[PMID] 35019780.
2022
Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial.
The Lancet. Respiratory medicine.
10(10):972-984
[DOI] 10.1016/S2213-2600(22)00215-6.
[PMID] 35817072.
2021
Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
73(11):2009-2022
[DOI] 10.1093/cid/ciab552.
[PMID] 34134131.
2021
Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir.
Journal of hepatology.
75(4):820-828
[DOI] 10.1016/j.jhep.2021.04.057.
[PMID] 34023351.
2021
Microbiota phylogenic analysis revealed decreased abundance of Faecalibacterium prausnitzii, an anti-inflammatory commensal bacterium, in patients with chronic graft-versus-host disease.
Hematology/oncology and stem cell therapy.
14(3):263-265
[DOI] 10.1016/j.hemonc.2021.03.004.
[PMID] 33785388.
2021
Stability of healthy subgingival microbiome across space and time.
Scientific reports.
11(1)
[DOI] 10.1038/s41598-021-03479-2.
[PMID] 34907334.
2021
Subgingival microbiome of deep and shallow periodontal sites in patients with rheumatoid arthritis: a pilot study.
BMC oral health.
21(1)
[DOI] 10.1186/s12903-021-01597-x.
[PMID] 33964928.
2020
A single variant sequencing method for sensitive and quantitative detection of HIV-1 minority variants.
Scientific reports.
10(1)
[DOI] 10.1038/s41598-020-65085-y.
[PMID] 32424187.
2020
Analysis of Tryptophan Metabolites in Serum Using Wide-Isolation Strategies for UHPLC-HRMS/MS.
Analytical chemistry.
92(3):2550-2557
[DOI] 10.1021/acs.analchem.9b04210.
[PMID] 31927994.
2020
Baseline Gut Microbiota Composition Is Associated with Major Infections Early after Hematopoietic Cell Transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
26(11):2001-2010
[DOI] 10.1016/j.bbmt.2020.07.023.
[PMID] 32717434.
2020
Muscadine Grapes (Vitis rotundifolia) and Dealcoholized Muscadine Wine Alleviated Symptoms of Colitis and Protected Against Dysbiosis in Mice Exposed to Dextran Sulfate Sodium
Journal of Functional Foods.
65
2020
Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial.
The Journal of infectious diseases.
222(Suppl 1):S8-S19
[DOI] 10.1093/infdis/jiaa259.
[PMID] 32645162.
2020
Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination.
HIV research & clinical practice.
21(1):11-23
[DOI] 10.1080/25787489.2020.1733794.
[PMID] 32160827.
2019
Decreased ω-6:ω-3 PUFA ratio attenuates ethanol-induced alterations in intestinal homeostasis, microbiota, and liver injury
.
60(12):2034-2049
2019
Decreased ω-6:ω-3 PUFA ratio attenuates ethanol-induced alterations in intestinal homeostasis, microbiota, and liver injury.
Journal of lipid research.
60(12):2034-2049
[DOI] 10.1194/jlr.RA119000200.
[PMID] 31586017.
2019
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy
Gastroenterology.
157(6):1506-1517.e1
[DOI] 10.1053/j.gastro.2019.08.008.
2019
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy
.
157(6):1506-1517
2019
Upper versus lower airway microbiome and metagenome in children with cystic fibrosis and their correlation with lung inflammation
PLOS ONE.
14(9)
[DOI] 10.1371/journal.pone.0222323.
[PMID] 31536536.
2018
Molecular Identification of Bacteria in Intra-abdominal Abscesses Using Deep Sequencing.
Open forum infectious diseases.
5(2)
[DOI] 10.1093/ofid/ofy025.
[PMID] 29479554.
2018
Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection.
Scientific reports.
8(1)
[DOI] 10.1038/s41598-018-21303-2.
[PMID] 29453451.
2018
The subgingival microbiome in patients with established rheumatoid arthritis.
Rheumatology (Oxford, England).
57(7):1162-1172
[DOI] 10.1093/rheumatology/key052.
[PMID] 29562298.
2017
Locoregional Effects of Microbiota in a Preclinical Model of Colon Carcinogenesis.
Cancer research.
77(10):2620-2632
[DOI] 10.1158/0008-5472.CAN-16-3472.
[PMID] 28416491.
2017
Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review.
Hepatology communications.
1(5):379-390
[DOI] 10.1002/hep4.1050.
[PMID] 29404466.
2017
Sequencing of hepatitis c virus for detection of resistance to direct-acting therapy: A systematic review.
.
1(5):379-390
2017
Shifts in the Gut Microbiota Composition Due to Depleted Bone Marrow Beta Adrenergic Signaling Are Associated with Suppressed Inflammatory Transcriptional Networks in the Mouse Colon.
Frontiers in physiology.
8
[DOI] 10.3389/fphys.2017.00220.
[PMID] 28446880.
2017
Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV).
Scientific reports.
7(1)
[DOI] 10.1038/s41598-017-15007-2.
[PMID] 29089577.
2016
An Integrated Metabolomic and Microbiome Analysis Identified Specific Gut Microbiota Associated with Fecal Cholesterol and Coprostanol in Clostridium difficile Infection.
PloS one.
11(2)
[DOI] 10.1371/journal.pone.0148824.
[PMID] 26871580.
2016
Biofilm Formation by Mycobacterium abscessus in a Lung Cavity.
American journal of respiratory and critical care medicine.
193(6):692-3
[DOI] 10.1164/rccm.201508-1586IM.
[PMID] 26731090.
2016
CD4+ T-cell recovery with suppressive ART-induced rapid sequence evolution in hepatitis C virus envelope but not NS3.
AIDS (London, England).
30(5):691-700
[DOI] 10.1097/QAD.0000000000000997.
[PMID] 26645605.
2015
Defining functional signatures of dysbiosis in periodontitis progression
Genome Medicine.
7(1)
[DOI] 10.1186/s13073-015-0165-z.
[PMID] 25926890.
2015
Dysbiosis and alterations in predicted functions of the subgingival microbiome in chronic periodontitis.
Applied and environmental microbiology.
81(2):783-93
[DOI] 10.1128/AEM.02712-14.
[PMID] 25398868.
2014
Colonic immune suppression, barrier dysfunction, and dysbiosis by gastrointestinal bacillus anthracis Infection.
PloS one.
9(6)
[DOI] 10.1371/journal.pone.0100532.
[PMID] 24945934.
2014
Epithelial CaSR deficiency alters intestinal integrity and promotes proinflammatory immune responses
.
588(22):4158-4166
2014
Epithelial CaSR deficiency alters intestinal integrity and promotes proinflammatory immune responses.
FEBS letters.
588(22):4158-66
[DOI] 10.1016/j.febslet.2014.05.007.
[PMID] 24842610.
2013
Deep sequencing analysis of HCV NS3 resistance-associated variants and mutation linkage in liver transplant recipients.
PloS one.
8(7)
[DOI] 10.1371/journal.pone.0069698.
[PMID] 23922778.
2013
Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea.
Journal of clinical microbiology.
51(9):2884-92
[DOI] 10.1128/JCM.00845-13.
[PMID] 23804381.
2013
Patient Preferences and Compliance With Oral Vancomycin Solution for the Management of Clostridium Difficile Infection
American Journal of Gastroenterology.
108(1)
2012
Loop residues and catalysis in OMP synthase
Biochemistry.
51(22):4406-4415
2011
A method to sequence and quantify DNA integration for monitoring outcome in gene therapy
.
39(11)
2011
Loss of p19Arf in a Rag1(-/-) B-cell precursor population initiates acute B-lymphoblastic leukemia
Blood.
118(3):544-553
2010
Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial
Blood.
115(22):4356-4366
2010
Hepatitis C virus transmission bottlenecks analyzed by deep sequencing
Journal Of Virology.
84(12):6218-6228
2010
Hepatitis C Virus Transmission Bottlenecks Analyzed By Deep Sequencing
Journal Of Virology.
84(12):6218-6228
[DOI] 10.1128/JVI.02271-09.
[PMID] 20375170.
2010
Transfusion independence and HMGA2 activation after gene therapy of human b-thalassaemia
Nature.
467(7313):318-322
2009
Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells.
Molecular therapy : the journal of the American Society of Gene Therapy.
17(5):844-50
[DOI] 10.1038/mt.2009.16.
[PMID] 19259065.
2009
Leukemia Prone B-Precursor Population in a P19Arf-/-Rag1-/- Mouse Model
Blood.
114
2009
Methods for integration site distribution analyses in animal cell genomes
Methods (San Diego, Calif.).
47(4):261-268
2008
Massively parallel pyrosequencing in HIV research.
AIDS (London, England).
22(12):1411-5
[DOI] 10.1097/QAD.0b013e3282fc972e.
[PMID] 18614863.
2007
DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations
Nucleic Acids Research.
35(13)
1999
Kinetic mechanism of OMP synthase: a slow physical step following group transfer limits catalytic rate
Biochemistry.
38(1):275-283
1999
motional dynamics of the catalytic loop in OMP synthase
Biochemistry.
38(1):275-283
1998
Making a nucleotide: structure and function of orotate phosphoribosyltransferase
.
6(1):1-11
1991
Local effect of glycine substitution in a model helical peptide
Journal of the American Chemical Society.
113:3568-3572
Grants
Jan 2024
ACTIVE
A rapid CRISPR-based self-testing platform for early detection of HIV
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAID
Oct 2023
ACTIVE
REBYOTA for the Management of Recurrent Clostridioides Difficile Infection (CDI) in
Adult Patients: An Observational Study
Role: Principal Investigator
Funding: FERRING PHARMACEUTICALS
Sep 2022
ACTIVE
A Phase 1b/2a, Randomized, Double-Blind, Placebo Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP-SA02 as an Adjunct to Best Available Antibiotic Therapy Compared to Best Available Antibiotic
Role: Principal Investigator
Funding: ARMATA PHARMACEUTICALS
via US DEPT OF DEFENSE
Jul 2022
ACTIVE
A randomized, open-label, multi-center, comparative trial, to assess the efficacy and safety of pritelivir versus foscarnet for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised subjects (PRIOH-1)
Role: Principal Investigator
Funding: AICURIS ANTI-INFECTIVE CURES
Jul 2022
– Jun 2024
A method for accurate and sensitive detection of HIV drug-resistant minority variants
Role: Principal Investigator
Funding: MEDOSOME BIOTEC
via NATL INST OF HLTH NIAID
Jun 2022
ACTIVE
Investigate the roles of gut microbiome in the differential responses of UTI susceptible women to cranberry juice intake
Role: Co-Investigator
Funding: US DEPT OF AG NATL INST OF FOOD AND AG
May 2022
ACTIVE
Rapid point-of-care detection of Hepatitis C viral RNA using multiplexed CRISPR/Cas platforms
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAID
May 2022
– Apr 2024
Gary Wang-IPA Agreement-Waters-FY23
Role: Other
Funding: US DEPT OF VET AFF GAINESVILLE MED CTR
Apr 2022
ACTIVE
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of the Efficacy, Safety, and Tolerability of a Single Oral Administration of CP101 for the Prevention of Recurrent Clostridioides difficile Infection
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC
via FINCH THERAPEUTICS
Oct 2021
– Sep 2023
VA IPA – Jennifer Gollwitzer
Role: Other
Funding: US DEPT OF VET AFF GAINESVILLE MED CTR
Sep 2021
– Aug 2024
Rapid detection of Hepatitis C virus using CRISPR/Cas
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAID
Jul 2021
ACTIVE
Next generation quantitative HCV drug resistance assay
Role: Principal Investigator
Funding: MEDOSOME BIOTEC
via NATL INST OF HLTH NIDDK
Nov 2020
ACTIVE
Industry Consortium Platform Trial to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients
Role: Principal Investigator
Funding: IQVIA LTD
via AMGEN INC
Nov 2020
– Oct 2021
Analysis of L. lactis strains in murine C. difficile model
Role: Principal Investigator
Funding: RISE THERAPEUTICS
via NATL INST OF HLTH NIAID
Jul 2020
– Jul 2022
DRPD-ROF2020: Determine the Metabolic Polymorphisms of American Cranberries to Prevent UTIs in Susceptible Women using an Integrated Metabolome-Microbiome Approach
Role: Co-Project Director/Principal Investigator
Funding: UF RESEARCH
Jul 2020
– Jul 2022
DRPD-ROF2020: Development of a Point-of-Care Platform for HIV Viral Load Testing
Role: Co-Project Director/Principal Investigator
Funding: UF RESEARCH
Jul 2020
– Dec 2021
Adaptive Platform Treatment Trial for Outpatients with COVID-19
Role: Principal Investigator
Funding: PPD DEVELOPMENT
via NATL INST OF HLTH NIAID
Jun 2020
– Jun 2025
A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome (ARDS) Secondary to Coronavirus Disease 2019 (COVID-19)
Role: Principal Investigator
Funding: PAREXEL INTERNATIONAL PTY
via KINEVANT SCIENCES
May 2020
– Sep 2023
SBIR – A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease.
Role: Co-Investigator
Funding: RISE THERAPEUTICS
via NATL INST OF HLTH NIDDK
Mar 2020
– Feb 2023
Cultivable commensal spores in C. difficile infection
Role: Principal Investigator
Funding: NATL INST OF HLTH NIAID
Feb 2020
– Jan 2022
Gary Wang-IPA Agreement-Sidhu
Role: Other
Funding: US DEPT OF VET AFF GAINESVILLE MED CTR
Nov 2019
– May 2021
A Phase 2b Randomized Blinded Study to Evaluate SYN023 Compared to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies in Adults with Different Rabies Exposure Risks
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC
via SYNERMORE BIOLOGICS
Oct 2019
– Aug 2021
Gary Wang IPA agreement (Joan Whitlock )
Role: Other
Funding: US DEPT OF VET AFF GAINESVILLE MED CTR
Sep 2019
ACTIVE
A Phase 3, Multi-Center, Randomized, Open-Label, Assessor-Blind Study to Evaluate the Efficacy and Safety of Mino-Lok Therapy (MLT) in Combination with Systemic Antibiotics in the Treatment of Catheter-Related or Central Line-Associated Bloodstream Infection
Role: Principal Investigator
Funding: MEDPACE
via LEONARD-MERON BIOSCIENCES
Jul 2019
– Jul 2024
A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (microbiota suspension) in Subjects with Recurrent Clostridium difficile Infection
Role: Principal Investigator
Funding: REBIOTIX
May 2019
– Jan 2021
A Double-Blind Placebo-Controlled Phase 2 Study of VE303
for Prevention of Recurrent Clostridium Difficile Infection
Role: Principal Investigator
Funding: PHARM OLAM
via VEDANTA BIOSCIENCES
Apr 2019
– Mar 2023
Synergistic interactions between muscadine wine and gut microbiota in alleviating intestinal inflammation and barrier dysfunction
Role: Co-Project Director/Principal Investigator
Funding: US DEPT OF AG NATL INST OF FOOD AND AG
Jan 2019
– Feb 2022
Gary Wang-IPA Agreement- Evan Waters
Role: Principal Investigator
Funding: US DEPT OF VET AFF GAINESVILLE MED CTR
Sep 2018
– Jul 2021
Developing the Biobehavioral Foundation for Self-Management of Psychoneurological Symptoms in Hematopoietic Cell Transplant (HCT) Survivors
Role: Co-Investigator
Funding: NATL INST OF HLTH NINR
Jul 2018
ACTIVE
CTOA
Role: Principal Investigator
Funding: UNIV OF FLORIDA
May 2018
– Dec 2020
To test the efficacy of a novel berberine emulsification using TPGS on the absorption of berberine compared to berberine powder in humans
Role: Co-Investigator
Funding: DESIGNS FOR HEALTH
Feb 2018
– Jan 2020
Gary Wang-IPA Agreement Gurjit, Sidhu,
Role: Other
Funding: US DEPT OF VET AFF GAINESVILLE MED CTR
Jan 2018
– Jun 2018
Use muscadine to reduce inflammation and promote optimal gut health
Role: Project Manager
Funding: FL DEPT OF AG AND CONSUMER SER
Nov 2017
– Aug 2021
An Open-label Efficacy and Safety Study of Rebiotix RBX2660 (microbiota suspension) for the Treatment of Recurrent Clostridium difficile Infection
Role: Principal Investigator
Funding: REBIOTIX
Oct 2017
– Sep 2019
Gary Wang IPA agreement (Joan Whitlock )
Role: Principal Investigator
Funding: US DEPT OF VET AFF GAINESVILLE MED CTR
Oct 2017
– Oct 2017
Gary Wang IPA agreement ( Lisa Zhao)
Role: Principal Investigator
Funding: *NF/SGVHS Malcom Randall VA Medical Cent
Apr 2017
– Mar 2019
Next generation quantitative HCV drug resistance assay
Role: Principal Investigator
Funding: MEDOSOME BIOTEC
via NATL INST OF HLTH NIDDK
Mar 2017
– Mar 2021
A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects with Chronic Hepatitis C Previously Treated with an NS5A Inhibitor + Sofosbuvir Therapy
Role: Project Manager
Funding: ABBVIE
May 2016
– Dec 2018
To determine the metabolomics and microbiome changes after cranberry juice consumption and bioactivity of cranberry phytochemicals – Confidential
Role: Co-Investigator
Funding: OCEAN SPRAY CRANBERRIES
May 2016
– Jun 2018
A MULTI CENTER RANDOMIZED DOUBLE BLIND STUDY TO COMPARE THE EFFICACY AND SAFETY OF CADAZOLID VERSUS VANCOMYCIN IN…….
Role: Principal Investigator
Funding: PPD DEVELOPMENT
via ACTELION PHARMACEUTICALS US
May 2016
– Apr 2018
Randomized Trial to Prevent Vascular Events in HIV (The REPRIEVE Study)
Role: Principal Investigator
Funding: MASSACHUSETTS GENERAL HOSPITAL
via NATL INST OF HLTH NHLBI
Apr 2016
– Sep 2021
Brain-Gut Microbiome-Immune Axis in Hypertension
Role: Project Manager
Funding: NATL INST OF HLTH NHLBI
Mar 2016
– Mar 2022
AN OPEN LABEL SAFETY ASSESSMENT OF REBIOTIX RBX2660 (MICROBIOTA SUSPENSION) FOR THE TREATMENT OF RECURRENT……
Role: Principal Investigator
Funding: REBIOTIX
Mar 2016
– Feb 2018
A method for accurate and sensitive detection of HIV drug-resistant minority variants
Role: Principal Investigator
Funding: MEDOSOME BIOTEC
via NATL INST OF HLTH NIAID
Dec 2015
– Feb 2019
Oral Metagenomic Biomarkers in Rheumatoid Arthritis
Role: Project Manager
Funding: US ARMY MED RES ACQUISITION
Jul 2015
– May 2018
Regulation of tryptophan metabolism and anxiety by gut microbiota
Role: Principal Investigator
Funding: NATL INST OF HLTH NIMH
Jun 2015
– May 2017
Mechanism of Microbial Signaling to the Brain: the Role of Serotonergic Pathway
Role: Principal Investigator
Funding: UF DSR OPPORTUNITY FUND
Apr 2015
– Apr 2018
A multi-Center, Randomized, Double Blind study to Compare the Efficancy and Safety of Cadazolid Versus Vancomycin in Subjects with Clostridium Difficile-Associated Diarrhea (CDAD)
Role: Principal Investigator
Funding: PPD DEVELOPMENT
via ACTELION PHARMACEUTICALS LTD
Mar 2014
– Feb 2022
Optimizing combination therapy for Hepatitis C virus with pharmacodynamic models
Role: Project Manager
Funding: NATL INST OF HLTH NIAID
Aug 2011
– Aug 2016
Naturally occurring mutations to Hepatitis C virus protease inhibitors analyzed by deep sequencing
Role: Principal Investigator
Funding: SCHERING PLOUGH RES INST
Jul 2007
– Aug 2016
Clinical and Translational Science Institute
Role: Project Manager
Funding: UF RESEARCH FOU
Education
Research Fellowship – Genomic Analysis of Retroviral Integration in Gene Therapy
2009
·
University of Pennsylvania School of Medicine
Fellowship – Infectious Diseases
2006
·
Hospital of the University of Pennsylvania
Residency – Internal Medicine
2004
·
Yale New-Haven Hospital
Medical School
2001
·
Temple University
Contact Details
Phones:
- Business:
- (352) 294-5481
Emails:
- Business:
- gary.wang@medicine.ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100289
GAINESVILLE FL 32610 - Business Street:
-
1600 SW ARCHER RD RM D2 14E
GAINESVILLE FL 32610